CANC Tema Oncology ETF

ETF

ETF quote, holdings, sector allocation, technicals, and options analytics. Fibonacci levels

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

CANC — —
Key stats
About

Tema Oncology ETF (CANC) ETF

No description available.

Exchange
XNAS
Inception
2023-08-14
Has Options
No
Fund profile
holdings as of Oct 1, 2026third-party datathrough May 2026flows, SEC filings
Thematic Biotech & Health Innovation#10 of 26 by assets Tema Actively managed
Expense ratio
0.75%
prospectus, filed Jun 29, 2026
Assets
$176M
SEC filing, May 31, 2026
Trailing yield
0.05%
paid annual
Average daily volume
$1.2M
30 sessions
Holdings
61
top 10 are 40.0%
Listed
Aug 14, 2023
Nasdaq
Closure risk, 12 months
1.8%
low · model
FrenzyCap ETF score
36
how it is built
Cost14
Liquidity36
Scale46
Diversification66

Moves with. US large-cap stocks (11% of its variance, beta 0.51); Small caps over large (9% of its variance, beta 0.56); Developed markets ex-US over US (6% of its variance, beta 0.57); Long Treasuries (5% of its variance, beta 0.37). These factors explain 33% of its daily moves over the last year, so most of what drives this fund is something else.

Stated objective. Tema Oncology ETF (the Fund) seeks to provide long-term growth. (from the fund's prospectus)

All 61 holdingsFlow historySimilar fundsOverlap toolAll Biotech & Health Innovation ETFs

Fund flows
through May 2026SEC filings
May 2026
−$2.3M
latest reported month
Latest 3 months
+$14M
+8.2% of assets
Latest 12 months
+$65M
+37.0% of assets
Jun 2025: +$2.2MJul 2025: −$6.9M−$6.9MJulAug 2025: +$533KSep 2025: +$3.8MSepOct 2025: +$615KNov 2025: +$4.5MNovDec 2025: +$14MJan 2026: +$24M+$24MJanFeb 2026: +$9.0MMar 2026: +$13MMarApr 2026: +$3.5MMay 2026: −$2.3MMay
View as a table
Net flows of CANC by month, Jun 2025 to May 2026
MonthNet flow
May 2026−$2.3M
Apr 2026+$3.5M
Mar 2026+$13M
Feb 2026+$9.0M
Jan 2026+$24M
Dec 2025+$14M
Nov 2025+$4.5M
Oct 2025+$615K
Sep 2025+$3.8M
Aug 2025+$533K
Jul 2025−$6.9M
Jun 2025+$2.2M

Net creations and redemptions from the fund's SEC filings, which become public about 60 days after each quarter. Every month since 34 months ago

Similar funds
FundOverlapFeeAssets1Y
HRTSTema ETF Trust Tema Heart & Health ETF30%0.75%$52M+15.4%compare
FTXHFirst Trust Nasdaq Pharmaceuticals ETF29%0.60%$1.1B+45.4%compare
AGNGGlobal X Funds Global X Aging Population ETF27%0.50%$92M+10.3%compare
XBIState Street SPDR S&P Biotech ETF25%0.35%$10.4B+38.7%compare
IDNAiShares Genomics Immunology and Healthcare ETF25%0.47%$325M+69.0%compare

Ranked by how much of the two portfolios is the same securities.

Look-through: what the holdings say
weights as of Oct 1, 2026third-party data
Holdings vs fair value
+6.0%
38% under, 23% over · 96% covered
Price / earnings
—
62% loss-making · 90% covered
Price / book · sales
7.0 · 8.4
revenue growth +8.6%
Above 200-day average
67%
43% above 50-day · by weight
Short interest
11.9%
of float, weighted · 6.3 days to cover
Insider buying
3%
of weight had net insider buying, 90 days; 54% net selling
13F holders
+7.5%
change in shares held by institutions, latest quarter
Reporting earnings
19.0%
of weight in 7 days; 70.6% in 14
Largest contributors below fair value
BMY+50%HALO+50%ELVN+50%IMNM+40%RLAY+43%
Largest contributors above fair value
ZLAB−50%ERAS−49%ZYME−50%MRK−12%ONC−13%

Each figure is the fund's holdings weighted by position size, using our data on those stocks, and covers only the share of the stock holdings stated. Positive fair value means the holdings trade below our estimate.

What changed in the portfolio
Feb 28, 2026 → May 31, 2026
ActionHoldingWeight beforeWeight afterShares vs flows
ExitACLXArcellx Inc3.44%——
DecreaseBBIOBridgebio Pharma Inc4.75%2.75%−41.4%
IncreaseLEGNLegend Biotech Corp1.37%2.99%+54.0%
DecreaseRVMDRevolution Medicines Inc6.29%7.73%−19.7%
New positionELVNEnliven Therapeutics Inc—1.31%—
IncreaseIMNMImmunome Inc2.67%3.91%+47.9%
New positionImmatics NV—1.12%—
IncreaseCELCCelcuity Inc2.47%3.58%+22.9%
DecreaseAstraZeneca PLC4.63%3.54%−13.1%
ExitNRIXNurix Therapeutics Inc0.97%——

Full holdings and history

Under the hood
fiscal year to Feb 28, 2026SEC census
Authorized participants
3 active
of 3 with agreements; top 3 did 100%
Created · redeemed
$62M · $7.4M
over the fiscal year
Redemptions in kind
99%
creations 98% in kind
Creation unit
10,000
shares
Securities lending
authorized, none lent
Diversification status
Non-diversified
may concentrate in fewer issuers

From the fund's annual census filing with the SEC. In-kind redemptions are what let an ETF shed appreciated securities without realising gains.

ETF Profile
holdings as of 2026-05-31
Holdings
57
AUM
$176.3M
Provider
Nport
Inception
2023-08-14
Exchange
XNAS
Data As Of
2026-05-31
Expense Ratio
0.75%
Dividend Yield
0.05%
Distribution
Annual
Recent distributions
Ex-Date Pay Date Amount Type
2025-12-10 2025-12-11 $0.0196 CD
2024-12-11 2024-12-12 $0.7283 CD
2023-12-13 2023-12-15 $0.1491 SC
Asset Allocation
Top Holdings
top 50 of 57 holdings
Symbol Name Weight % Asset Class Country
RVMD Revolution Medicines Inc 7.73% Equity (common) US
LLY Eli Lilly & Co 4.82% Equity (common) US
RHHBY Roche Holding AG 4.21% Equity (common) CH
COGT Cogent Biosciences Inc 4.10% Equity (common) US
— Novartis AG 4.03% Equity (common) CH
IMNM Immunome Inc 3.91% Equity (common) US
CELC Celcuity Inc 3.58% Equity (common) US
MRK Merck & Co Inc 3.57% Equity (common) US
— AstraZeneca PLC 3.54% Equity (common) GB
NUVL Nuvalent Inc 3.37% Equity (common) US
BMY Bristol-Myers Squibb Co 3.30% Equity (common) US
LEGN Legend Biotech Corp 2.99% Equity (common) US
ABBV AbbVie Inc 2.81% Equity (common) US
EXEL Exelixis Inc 2.78% Equity (common) US
BBIO Bridgebio Pharma Inc 2.75% Equity (common) US
JNJ Johnson & Johnson 2.55% Equity (common) US
CGON CG oncology Inc 2.43% Equity (common) US
GMAB Genmab A/S 2.37% Equity (common) DK
IDYA Ideaya Biosciences Inc 2.27% Equity (common) US
AMGN Amgen Inc 2.11% Equity (common) US
ZLAB Zai Lab Ltd 1.98% Equity (common) CN
ONC BeOne Medicines Ltd 1.88% Equity (common) US
ZYME Zymeworks Inc 1.51% Equity (common) US
ELVN Enliven Therapeutics Inc 1.31% Equity (common) US
RLAY Relay Therapeutics Inc 1.28% Equity (common) US
HALO Halozyme Therapeutics Inc 1.23% Equity (common) US
SMMT Summit Therapeutics Inc 1.21% Equity (common) US
RCUS Arcus Biosciences Inc 1.20% Equity (common) US
GILD Gilead Sciences Inc 1.12% Equity (common) US
— Immatics NV 1.12% Equity (common) DE
— First American Treasury Obliga 1.09% Short-term investment US
ERAS Erasca Inc 1.08% Equity (common) US
NUVB Nuvation Bio Inc 1.07% Equity (common) US
ANAB AnaptysBio Inc 0.99% Equity (common) US
— UroGen Pharma Ltd 0.93% Equity (common) US
GH Guardant Health Inc 0.81% Equity (common) US
SNDX Syndax Pharmaceuticals Inc 0.80% Equity (common) US
CRVS Corvus Pharmaceuticals Inc 0.76% Equity (common) US
REGN Regeneron Pharmaceuticals Inc 0.75% Equity (common) US
AVBP ArriVent Biopharma Inc 0.73% Equity (common) US
— Chugai Pharmaceutical Co Ltd 0.67% Equity (common) JP
IOVA Iovance Biotherapeutics Inc 0.65% Equity (common) US
INBX Inhibrx Biosciences Inc 0.60% Equity (common) US
OLMA Olema Pharmaceuticals Inc 0.60% Equity (common) US
CGEM Cullinan Therapeutics Inc 0.59% Equity (common) US
NTRA Natera Inc 0.54% Equity (common) US
TRAX First Tracks Biotherapeutics I 0.53% Equity (common) US
IMCR Immunocore Holdings PLC 0.51% Equity (common) GB
BBOT BridgeBio Oncology Therapeutic 0.48% Equity (common) US
CTMX CytomX Therapeutics Inc 0.47% Equity (common) US
Geographic Breakdown
Non-Equity Breakdown
Tema Oncology ETF · NPORT-P period 2026-05-31 (filed 2026-07-29)
Net assets: $176M · 57 total positions · equity 98.99% · non-equity 1.09%
Non-equity holdings — 1 positions, 1.09% of NAV
Category Weight Value Positions
Short-term investment 1.09% $1.9M 1
Chart
Seasonality
'23'24'25'26Avg
Jan---1.73%5.11%3.38%2.25%
Feb--5.58%1.47%3.60%3.55%
Mar---1.99%-3.90%-2.02%-2.64%
Apr---4.90%6.48%1.04%0.87%
May---0.48%-2.07%2.55%0.00%
Jun---0.19%1.41%10.68%3.97%
Jul--8.58%4.69%-0.55%4.24%
Aug0.01%3.21%2.78%7.53%3.38%
Sep-8.49%-1.56%6.87%-3.82%-1.75%
Oct-3.11%-1.98%6.07%0.55%*0.38%
Nov8.21%-0.31%16.60%--8.17%
Dec7.81%-12.52%-1.11%---1.94%
Total3.45%-9.42%52.43%24.46%17.73%
* Only 4 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $40.87
SMA 50: $42.25
SMA 200: $39.07
Current: $41.53
EMA 12: $40.72
EMA 26: $41.11
MACD: -0.3812 | Signal: 0.1455
BEARISH
ADX (14): 19.89
RANGE
+DI: 26.92
−DI: 25.80

Momentum Oscillators

RSI (14): 52.61
NEUTRAL
Stoch %K: 64.31
Stoch %D: 44.81
Williams %R: -15.61

Volume & Volatility

BB Upper: $42.44
BB Lower: $39.29
NEUTRAL
OBV: 645,056
Vol SMA 20: 27,348
Vol ROC: -31.61%
ATR: $0.97
True Range: $0.54
HV 20: 26.9%
HV 30: 26.2%
HV 60: 25.2%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis

Click Frenzy-Pro™ for an AI analysis of this ticker.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

CANC Options Activity & IV Rank

Loading options activity...
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis

Risk Metrics

Beta: 0.7466
Alpha: 23.29%
Correlation: 0.4022
R-Squared: 16.2%
Stock Volatility: 23.6%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Beta & Alpha Over Time

CANC Institutional Ownership (13F)

Latest filings — 2026-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

15 filers645,179 shares$25.98M value
# Filer Shares Value % of Total % of Float Period
1 Thrivent Financial for Lutherans 186,062 $7.67M 29.54% — 2026-06-30
2 LPL Financial LLC Custodian 138,824 $5.73M 22.04% — 2026-06-30
3 Willow Financial LLC 139,662 $5.12M 19.73% — 2026-03-31
4 HighTower Advisors, LLC 76,401 $3.15M 12.13% — 2026-06-30
5 Jane Street Group, LLC Custodian 27,537 $1.14M 4.37% — 2026-06-30
6 Stratos Wealth Partners, LTD. 19,403 $800.18K 3.08% — 2026-06-30
7 Perennial Investment Advisors, LLC 19,182 $791.07K 3.05% — 2026-06-30
8 Oder Investment Management, LLC 12,403 $511.50K 1.97% — 2026-06-30
9 Royal Bank of Canada Custodian 7,849 $324.00K 1.25% — 2026-06-30
10 WJ Wealth Management, LLC 6,850 $282.49K 1.09% — 2026-06-30
11 Cambridge Investment Research Advisors, Inc. 5,335 $220.00K 0.85% — 2026-06-30
12 Roxbury Financial LLC 4,325 $181.69K 0.70% — 2026-09-30
13 US BANCORP \DE\ Custodian 600 $24.74K 0.10% — 2026-06-30
14 TD Capital Management LLC 376 $15.52K 0.06% — 2026-06-30
15 OSAIC HOLDINGS, INC. Custodian 370 $15.26K 0.06% — 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period
CANC Constituent Performance

Click any bar to view the full quote for that stock.

CANC Constituents (50 of 51)
Symbol Name Weight % Price 1 Day 1 Week 1 Month
RVMD Revolution Medicines Inc 7.73% $194.28 -1.15%+0.39%+1.86%
LLY Eli Lilly & Co 4.82% $1270.75 -1.01%+5.13%+10.40%
COGT Cogent Biosciences Inc 4.10% $31.43 +0.61%+11.65%+0.06%
IMNM Immunome Inc 3.91% $18 +0.45%+4.65%-25.74%
CELC Celcuity Inc 3.58% $61.56 +2.60%+2.77%-23.04%
MRK Merck & Co Inc 3.57% $149.88 +1.07%+1.70%+1.22%
NUVL Nuvalent Inc 3.37% $123.96 +0.02%+0.15%+0.58%
BMY Bristol-Myers Squibb Co 3.30% $61.12 -0.91%+3.10%-0.05%
LEGN Legend Biotech Corp 2.99% $18.63 -2.00%-2.15%+0.98%
ABBV AbbVie Inc 2.81% $284.8 -1.48%+0.47%+7.44%
EXEL Exelixis Inc 2.78% $64.58 +0.30%+5.89%+13.84%
BBIO Bridgebio Pharma Inc 2.75% $67.74 +0.28%+4.31%+3.09%
JNJ Johnson & Johnson 2.55% $257.78 -0.61%+1.52%-4.23%
CGON CG oncology Inc 2.43% $62.24 +0.50%+0.65%-15.16%
GMAB Genmab A/S 2.37% $39.57 +1.28%+7.26%+13.87%
IDYA Ideaya Biosciences Inc 2.27% $35.47 +0.31%+4.75%-5.31%
AMGN Amgen Inc 2.11% $438.34 -0.14%+2.87%+7.94%
ZLAB Zai Lab Ltd 1.98% $24.2 -3.51%+7.56%-8.47%
ONC BeOne Medicines Ltd 1.88% $386.46 +0.51%+9.95%+5.88%
ZYME Zymeworks Inc 1.51% $28.11 +4.48%+13.50%+2.24%
ELVN Enliven Therapeutics Inc 1.31% $41.82 +1.38%+6.47%-9.26%
RLAY Relay Therapeutics Inc 1.28% $18.41 -0.22%+7.91%+2.11%
HALO Halozyme Therapeutics Inc 1.23% $124.83 +0.37%+6.86%+11.02%
SMMT Summit Therapeutics Inc 1.21% $15.83 -1.62%+4.63%-3.77%
RCUS Arcus Biosciences Inc 1.20% $19.1 -19.58%-15.22%-27.62%
GILD Gilead Sciences Inc 1.12% $153.57 -1.88%+0.02%+1.45%
ERAS Erasca Inc 1.08% $14.49 -0.89%-1.43%+3.91%
NUVB Nuvation Bio Inc 1.07% $4.85 +1.68%+3.63%-15.06%
ANAB AnaptysBio Inc 0.99% $47.94 +5.52%+2.72%-5.57%
GH Guardant Health Inc 0.81% $166.66 +2.50%+2.25%-5.47%
SNDX Syndax Pharmaceuticals Inc 0.80% $13.15 -0.75%-2.81%-25.45%
CRVS Corvus Pharmaceuticals Inc 0.76% $10.05 -1.76%+7.14%-19.86%
REGN Regeneron Pharmaceuticals Inc 0.75% $805.67 -0.22%+3.51%+0.48%
AVBP ArriVent Biopharma Inc 0.73% $19.12 +1.43%+18.02%-36.90%
IOVA Iovance Biotherapeutics Inc 0.65% $14.62 -1.62%+2.89%+43.47%
INBX Inhibrx Biosciences Inc 0.60% $98.19 +3.03%+15.17%-2.13%
OLMA Olema Pharmaceuticals Inc 0.60% $7.05 -2.76%+3.68%-20.16%
CGEM Cullinan Therapeutics Inc 0.59% $14.89 +0.40%+9.16%-11.74%
NTRA Natera Inc 0.54% $413.38 +1.84%+4.72%+5.78%
TRAX First Tracks Biotherapeutics I 0.53% $42.77 +3.68%+25.31%+16.67%
IMCR Immunocore Holdings PLC 0.51% $32.09 -1.56%+13.23%+1.74%
BBOT BridgeBio Oncology Therapeutic 0.48% $2.68 -1.47%-7.75%-35.58%
CTMX CytomX Therapeutics Inc 0.47% $2.4 -4.38%+7.62%-13.67%
HCM HUTCHMED China Ltd 0.44% $14.37 -2.51%+6.60%+0.00%
ARVN Arvinas Inc 0.43% $7.55 -1.37%+10.78%-3.51%
JANX Janux Therapeutics Inc 0.43% $16.93 -1.57%-1.17%+2.48%
ANL Adlai Nortye Ltd 0.30% $11.26 +5.83%+3.49%-28.51%
TYRA Tyra Biosciences Inc 0.30% $20.6 +0.64%+10.16%-11.32%
ORIC ORIC Pharmaceuticals Inc 0.28% $13.85 +0.51%+19.50%+3.90%
SLS SELLAS Life Sciences Group Inc 0.22% $12.14 +1.34%+2.19%+5.38%